SEGMENT INFORMATION (Major Customers) (Details)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Gilead Sciences, Inc. [Member] | Sales [Member]
Revenue, Major Customer [Line Items]
Concentration risk, percentage	4.40%	7.30%
Gilead Sciences, Inc. [Member] | Accounts Receivable [Member]
Revenue, Major Customer [Line Items]
Concentration risk, percentage	0.70%	7.40%
Pfizer, Inc. [Member] | Sales [Member]
Revenue, Major Customer [Line Items]
Concentration risk, percentage	4.90%	3.40%
Pfizer, Inc. [Member] | Accounts Receivable [Member]
Revenue, Major Customer [Line Items]
Concentration risk, percentage	3.30%	8.40%
Boehringer Ingelheim [Member] | Sales [Member]
Revenue, Major Customer [Line Items]
Concentration risk, percentage	6.00%	2.60%
Boehringer Ingelheim [Member] | Accounts Receivable [Member]
Revenue, Major Customer [Line Items]
Concentration risk, percentage	3.30%	4.30%